Hansa Biopharma AB

Active trials

• phase2Imlifidase Prior to Kidney Transplant in Highly Sensitised Childrenrecruitingn=10
• phase3A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Grouprecruitingn=150
• phase3Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohortsactive not recruitingn=225
• phase3A Study With Imlifidase in Anti-GBM Diseaseterminatedn=50
• —Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneysactive not recruitingn=64
• phase2A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantationterminatedn=3
• phase3Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Txcompletedn=64
• —An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMRterminatedn=18